Evidence map›Paper›PMID 36382801›Full record

ArticleDiabetes care2023

Development of a Clinical Prediction Model for Diabetes in Chronic Pancreatitis: The PREDICT3c Study.

Christie Jeon, Phil A Hart, Liang Li, Yunlong Yang, Eleanor Chang, Melena D Bellin, William E Fisher, Evan L Fogel, Christopher E Forsmark, Walter G Park and 8 more

Open access · greenAbstract read
In one paragraph

Article in Diabetes care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Observational
  2. Approach to the Patient With Pancreatogenic Diabetes.The Journal of clinical endocrinology and metabolism · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Risk Factors and Mechanisms for Diabetes in Pancreatitis.Gastroenterology clinics of North America · 2025
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 12 institutions in 1 country.

Christie JeonSamuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
Phil A HartDivision of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH.ORCID 0000-0003-4346-6196
Liang LiDepartment of Biostatistics, MD Anderson Cancer Center, Houston, TX.
Yunlong YangDepartment of Biostatistics, MD Anderson Cancer Center, Houston, TX.
Eleanor ChangSamuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
Melena D BellinDivision of Endocrinology and Metabolism, Department of Pediatrics, University of Minnesota Medical Center, Minneapolis, MN.ORCID 0000-0002-7324-4837
William E FisherDepartment of Surgery, Baylor College of Medicine, Houston, TX.
Evan L FogelDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University Medical Center, Indianapolis, IN.
Christopher E ForsmarkDivision of Gastroenterology, Hepatology, and Nutrition, University of Florida, Gainesville, FL.
Walter G ParkDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA.
Stephen K Van Den EedenDivision of Research, Kaiser Permanente Northern California, Oakland, CA.
Santhi Swaroop VegeDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
Jose SerranoDivision of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
David C WhitcombDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Pittsburgh and UPMC Medical Center, Pittsburgh, PA.
Dana K AndersenDivision of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Darwin L ConwellDivision of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH.
Dhiraj YadavDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Pittsburgh and UPMC Medical Center, Pittsburgh, PA.ORCID 0000-0001-7078-9893
Mark O GoodarziDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0001-6364-5103
Cedars-Sinai Medical Center · USNational Institutes of Health · USThe Ohio State University Wexner Medical Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of Pittsburgh Medical Center · USBaylor College of Medicine · USKaiser Permanente · USMayo Clinic in Arizona · USStanford University · USUniversity Medical Center · USUniversity of Florida · USUniversity of Minnesota Medical Center · US

Funding

Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MILES Frome WILKINSON · 2003 to 2026
$40.4M
Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer: Coordinating and Data Management Center (CSCPDPC-CDMC)U01DK108328 · NIDDK · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Liang Li, Suyu Liu · 2015 to 2026
$32.8M
Indiana University (IU) Clinical Center for Chronic Pancreatitis Clinical Research NetworkU01DK108323 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Jeffrey James Easler, Evan L Fogel · 2015 to 2026
$6.5M
UPMC Clinical Center for the Study of Chronic Pancreatitis and DiabetesU01DK108306 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Frederico G. S. Toledo, Dhiraj Yadav · 2015 to 2026
$6.4M
The Stanford Clinical Center for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic CancerU01DK108300 · NIDDK · STANFORD UNIVERSITY · PI Sohail Z Husain, Walter Gwang-Up Park · 2015 to 2026
$6.3M
Pathophysiology, Epidemiology, and Prevention of Pancreatogenic Diabetes - Administrative SupplementU01DK108314 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI Mark Goodarzi, Stephen J. Pandol · 2015 to 2026
$6.1M
The Exocrine and Endocrine Pancreas in Type 2 Diabetes, Pancreatitis and Cancer (Admin Supplement)U01DK108288 · NIDDK · MAYO CLINIC ROCHESTER · PI Santhi Swaroop Vege · 2015 to 2026
$5.9M
The Ohio State University Pancreatic Disorders Network (OSU-PDN)U01DK108327 · NIDDK · OHIO STATE UNIVERSITY · PI CONWELL, DARWIN LEWIS, HART, PHILIP A. · 2015 to 2024
$5.5M
DYSBIOTIC MICROBIOME IN PANCREATITIS, DIABETES, AND PANCREATIC CANCERU01DK108326 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI FISHER, WILLIAM E · 2015 to 2024
$5.2M
U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERSU01DK108320 · NIDDK · UNIVERSITY OF FLORIDA · PI CUSI, KENNETH, FORSMARK, CHRISTOPHER E · 2015 to 2024
$4.6M
University of Minnesota Clinical Center for the Study of Pancreatic DiseaseU01DK126300 · NIDDK · UNIVERSITY OF MINNESOTA · PI GREGORY J BEILMAN, Melena D. Bellin · 2020 to 2026
$3.9M
Chronic Pancreatitis, Diabetes and Pancreatic Cancer: A Prospective ApproachU01DK108332 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI VAN DEN EEDEN, STEPHEN K. · 2015 to 2019
$1.9M
NIDDK NIH HHS P30 DK063491NIDDK NIH HHS U01 DK108288NIDDK NIH HHS U01 DK108300NIDDK NIH HHS U01 DK108306NIDDK NIH HHS U01 DK108314NIDDK NIH HHS U01 DK108320NIDDK NIH HHS U01 DK108323NIDDK NIH HHS U01 DK108326NIDDK NIH HHS U01 DK108327NIDDK NIH HHS U01 DK108328NIDDK NIH HHS U01 DK108332NIDDK NIH HHS U01 DK126300
6 · The paper itself

Abstract

objectiveDiabetes that arises from chronic pancreatitis (CP) is associated with increased morbidity and mortality. Methods to predict which patients with CP are at greatest risk for diabetes are urgently needed. We aimed to examine independent risk factors for diabetes in a large cohort of patients with CP. RESEARCH DESIGN AND

methodsThis cross-sectional study comprised 645 individuals with CP enrolled in the PROCEED study, of whom 276 had diabetes. We conducted univariable and multivariable regression analyses of potential risk factors for diabetes. Model performance was assessed by area under the receiver operating characteristic curve (AUROC) analysis, and accuracy was evaluated by cross validation. Exploratory analyses were stratified according to the timing of development of diabetes relative to the diagnosis of pancreatitis.

resultsIndependent correlates of diabetes in CP included risk factors for type 2 diabetes (older age, overweight/obese status, male sex, non-White race, tobacco use) as well as pancreatic disease-related factors (history of acute pancreatitis complications, nonalcoholic etiology of CP, exocrine pancreatic dysfunction, pancreatic calcification, pancreatic atrophy) (AUROC 0.745). Type 2 diabetes risk factors were predominant for diabetes occurring before pancreatitis, and pancreatic disease-related factors were predominant for diabetes occurring after pancreatitis.

conclusionsMultiple factors are associated with diabetes in CP, including canonical risk factors for type 2 diabetes and features associated with pancreatitis severity. This study lays the groundwork for the future development of models integrating clinical and nonclinical data to identify patients with CP at risk for diabetes and identifies modifiable risk factors (obesity, smoking) on which to focus for diabetes prevention.

Indexed as

Diabetes Mellitus, Type 2Pancreatitis, ChronicAcute DiseaseCross-Sectional StudiesHumansMaleModels, StatisticalObesityPrognosisRisk Factors

Identifiers

PMID36382801
PMCPMC9797648
OpenAlexW4309165320

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.